Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs SAP SE (SAP) Price & Performance

Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs SAP SE — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while SAP SE trades at $203.72 (market cap $240.81B). The key difference: SAP SE is far larger — about 14.2× Medpace Holdings Inc's market cap, and SAP SE pays a 1.4% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

MEDPSAP
Market Cap
$16.90B$240.81B
Sector
TechnologyTechnology
52-Week High
$620.59$280.46
52-Week Low
$393.42$146.38
Enterprise Value
$16.52B$239.52B
Dividend Yield
1.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

SAP SE

SAP trades at $204.035, down 2.16% today, with a bullish technical trend supported by moving averages but overbought RSI signals. Revenue grew to $36.8B in 2025 with a strong net income margin of 20.41%, though Q2 2026 EPS missed estimates. Recent news highlights AI and cloud momentum, with shares reacting positively to Q2 results despite profit guidance concerns.

Outlook is cautiously optimistic with a consensus price target of $209.67, offering modest upside. Risks include execution challenges in AI integration and margin pressure from rising costs. The stock presents a growth opportunity driven by cloud adoption, but investors should weigh valuation multiples against earnings consistency.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About SAP SE

Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.

Read more on SAP